Inhibition of phosphodiesterase 4B as a novel therapeutic strategy for the treatment of refractory epilepsy.
Kinch CD, Kesler M, Dogra DD, Morin K, Ibhazehiebo K, Noschang CG, Rho JM, Kurrasch DM — 17 May 2025 (preprint)
Selective allosteric inhibition of phosphodiesterase 4B (PDE4B) as a potential anti-seizure treatment for Dravet Syndrome
Kinch, CD, et al., American Epilepsy Society 2024 Dec
A concise synthesis of biaryl PDE4D allosteric modulators
Dalby, A, et al.,Tetrahedron Lett. 2013
LINK IS NO LONGER AVAILABLE
kcna1a Mutant Zebrafish model episodic Ataxia type 1 (EA1) with epilepsy and show response to first-line therapy carbamazepine
Dogra, D., Epilepsia 2018 Mar
Metabolism-based drug discovery in zebrafish: An emerging strategy to uncover new anti-seizure therapies.
Ibhazehiebo, K, et al., 2020 May
Metabolism-based drug discovery in zebrafish: an emerging strategy to uncover new anti-seizure therapies.
Ibhazehiebo K, Rho JM, Kurrasch DM — 2020
Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of Fragile X Syndrome and other brain disorders.
Gurney, ME, et al. J Med Chem. 2019 May
A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target.
Ibhazehiebo K, Gavrilovici C, de la Hoz CL, Ma SC, Rehak R, Kaushik G, Meza Santoscoy PL, Scott L, Nath N, Kim DY, Rho JM, Kurrasch DM — 24 January 2018
A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target
Ibhazehiebo, K, et al., Brain, 2018 Mar
Discovery of triazines as selective PDE4B versus PDE4D inhibitors
Dogra, D., Epilepsia 2018 Mar